Q-omics provides the consensus-scored ALG1L3P profile across patient tissues and cancer cell-line models. ALG1L3P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ALG1L3P is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ALG1L3P RNA expression shows 8,924 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, COAD, and TGCT as cancer lineages where ALG1L3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALG1L3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALG1L3P survival associations across molecular data types. ALG1L3P RNA expression shows survival associations in the most cancer types (18), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALG1L3P RNA expression–survival associations across cancer types. High ALG1L3P expression shows unfavorable associations in BRCA, UCEC, LUAD and KIRC, but favorable associations in UCS and COAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify BRCA as the clearest survival context for ALG1L3P RNA expression.
This table summarizes ALG1L3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for ALG1L3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALG1L3P shows higher tumor expression in COAD, LUAD, STAD, LUSC, UCEC and BRCA. The COAD box plot shows higher ALG1L3P RNA expression in tumor versus normal tissue (log2 FC = +1.068, t-test p < 0.001).
This table shows molecular features associated with ALG1L3P in patient tissues and cancer cell lines. In patient samples, ALG1L3P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
